PPIDT00176
Drug Information
| Name | Leronlimab |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB05941 |
| Type | biotech |
| Indication | Leronlimab is currently being investigated for the treatment of a number of cancers[A192858] and HIV.[A3922] Recently leronlimab has begun a phase II clinical trial in severely ill COVID-19 patients.[L12684] Preliminary data shows a reduction in the 'cytokine storm', particularly IL-6, as well as a normalization of the CD4/CD8 T-cell ratio.[L12684] These results may mitigate immune mediate injury seen in severely ill COVID-19 patients.[L12684] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| No dosage records. | ||